,datetime,sentence,positive,negative,neutral,global_sentiment,avg_sentiment
0,2015-01-28 09:30:00,"St. Jude Medical Inc. ( STJ ) reported adjusted EPS of $1.03, which was in line with the Zacks Consensus Estimate.",0.28375720977783203,0.07027482241392136,0.645967960357666,neutral,0.21348237991333008
1,2015-01-28 09:30:00,"EPS increased 4% year over year driven by a modest 1.2% rise in total sales to $1.44 billion, which also met the Zacks Consensus Estimate.",0.9599108099937439,0.019435923546552658,0.020653292536735535,positive,0.9404748678207397
2,2015-01-28 09:30:00,"At constant currency (cc), total sales increased 5% on a year-over-year basis.",0.9596596956253052,0.017958056181669235,0.02238219603896141,positive,0.9417016506195068
3,2015-01-28 09:30:00,"International sales declined 2.6% (up 4% at cc) to $761 million, while U.S. sales increased 5.8% to $678 million in the quarter.",0.02730361744761467,0.9640349745750427,0.008661461994051933,negative,-0.9367313385009766
4,2015-01-28 09:30:00,Cardiac Rhythm Management (CRM) sales decreased 2.8% (up 1% at cc) year over year to $685 million.,0.017476839944720268,0.9734798073768616,0.009043337777256966,negative,-0.956002950668335
5,2015-01-28 09:30:00,U.S. sales were almost flat at $336 million while international sales fell 5.6% (up 1% at cc) to $349 million in the said quarter.,0.01812657155096531,0.9718174934387207,0.010055935941636562,negative,-0.9536909461021423
6,2015-01-28 09:30:00,"In the CRM division, implantable cardiac defibrillator (ICD) sales declined 3.6% to $426 million, while pacemaker sales fell 1.5% to $259 million.",0.017672425135970116,0.9730365872383118,0.009291015565395355,negative,-0.9553641676902771
7,2015-01-28 09:30:00,CardioMEMS HF systems sales were approximately $12 million in the quarter.,0.030204052105545998,0.007475499529391527,0.9623204469680786,neutral,0.022728553041815758
8,2015-01-28 09:30:00,Atrial Fibrillation (AF) sales jumped 12.3% year over year (up 17% at cc) to $283 million.,0.9556117057800293,0.023264599964022636,0.021123671904206276,positive,0.9323471188545227
9,2015-01-28 09:30:00,"International sales grew 11% to $171 million, while U.S. sales increased 14.3% to $112 million in the quarter.",0.9526693224906921,0.01910894177854061,0.028221774846315384,positive,0.9335603713989258
10,2015-01-28 09:30:00,Cardiovascular sales declined almost 1% (up 3% at cc) to $347 million in the quarter.,0.016913309693336487,0.9724810719490051,0.010605575516819954,negative,-0.9555677771568298
11,2015-01-28 09:30:00,"International sales plunged 10.1% to $214 million, while U.S. sales soared 18.8% to $133 million.",0.06597645580768585,0.9182034134864807,0.015820153057575226,negative,-0.852226972579956
12,2015-01-28 09:30:00,"In the Cardiovascular division, vascular product revenues climbed 2.7% to $188 million.",0.9553579092025757,0.02163415029644966,0.023007869720458984,positive,0.9337237477302551
13,2015-01-28 09:30:00,"Meanwhile, structural heart product revenues decreased 4.8% to $159 million in the quarter.",0.01684519648551941,0.9742175340652466,0.008937397971749306,negative,-0.9573723077774048
14,2015-01-28 09:30:00,"Neuromodulation sales jumped 7.8% year over year to $124 million, driven by 21.2% surge in the U.S. sales and 2.4% increase in international sales.",0.9544622898101807,0.023664893582463264,0.021872760728001595,positive,0.9307973980903625
15,2015-01-28 09:30:00,"For the first quarter of 2015, St. Jude expects sales to grow in the range of 2% to 4% at cc.",0.8762761950492859,0.011940772645175457,0.11178303509950638,positive,0.8643354177474976
16,2015-01-28 09:30:00,Foreign exchange volatility is expected to negatively impact sales by approximately $85 to $100 million.,0.018282052129507065,0.9218413829803467,0.059876538813114166,negative,-0.9035593271255493
17,2015-01-28 09:30:00,The Zacks Consensus Estimate for sales is currently pegged at $1.37 billion.,0.017808791249990463,0.009639770723879337,0.9725514054298401,neutral,0.008169020526111126
18,2015-01-28 09:30:00,"EPS for the first quarter is forecasted in the range of 90 to 92 cents, which is lower than the current Zacks Consensus Estimate of 97 cents.",0.017550736665725708,0.9286115765571594,0.05383775010704994,negative,-0.9110608100891113
19,2015-01-28 09:30:00,"For full-year 2015, St. Jude expects sales to grow in the range of 3% to 5% at cc.",0.9025124907493591,0.01257888600230217,0.08490869402885437,positive,0.8899335861206055
20,2015-01-28 09:30:00,Foreign exchange volatility is expected to negatively impact sales by approximately $325 to $350 million.,0.018125995993614197,0.9254217147827148,0.05645221471786499,negative,-0.9072957038879395
21,2015-01-28 09:30:00,The Zacks Consensus Estimate for the same is currently pegged at $5.72 billion.,0.021827835589647293,0.008148792199790478,0.9700233936309814,neutral,0.013679043389856815
22,2015-01-28 09:30:00,"EPS is projected in the range of $3.95 to $4.00, which is lower than the current Zacks Consensus Estimate of $4.12.",0.023211993277072906,0.8379018902778625,0.13888610899448395,negative,-0.8146898746490479
23,2015-01-28 09:30:00,St. Jude's fourth-quarter 2014 results reflect strong momentum at the company's CardioMEMS technology and Atrial Fibrillation business.,0.9525956511497498,0.015749141573905945,0.03165511041879654,positive,0.9368464946746826
24,2015-01-28 09:30:00,"We believe that an expanding and innovative product portfolio, accretive acquisitions and aggressive share buyback programs will drive growth in 2015.",0.9208917021751404,0.012070504948496819,0.06703777611255646,positive,0.9088212251663208
25,2015-01-28 09:30:00,"However, we feel that the strong U.S. dollar which is impacting the company's revenues will also hurt its bottom line.",0.023108895868062973,0.9565587639808655,0.020332319661974907,negative,-0.9334498643875122
26,2015-01-28 09:30:00,"Moreover, the prevailing tight spending environment remains a major headwind.",0.029593758285045624,0.9220327734947205,0.04837346076965332,negative,-0.8924390077590942
27,2015-01-28 09:30:00,"Better-ranked stocks in the same sector are ICU Medical ( ICUI ), Phibro Animal Health ( PAHC ) and Nxstage Medical ( NXTM ).",0.47450631856918335,0.03480667993426323,0.49068698287010193,neutral,0.439699649810791
28,2015-01-28 09:30:00,All the companies sport a Zacks Rank #1 (Strong Buy).,0.5362495183944702,0.02251095324754715,0.4412395656108856,positive,0.5137385725975037
29,2015-01-28 09:30:00,Want the latest recommendations from Zacks Investment Research?,0.03539300337433815,0.011573811061680317,0.9530332088470459,neutral,0.023819193243980408
30,2015-01-28 09:30:00,"Today, you can download 7 Best Stocks for the Next 30 Days.",0.05069374665617943,0.007019795011729002,0.9422864317893982,neutral,0.04367395117878914
31,2015-01-28 09:30:00,"Click to get this free report

To read this article on Zacks.com click here.",0.02068457007408142,0.033159855753183365,0.9461556077003479,neutral,-0.012475285679101944
32,2015-01-28 09:30:00,"The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.",0.010204566642642021,0.01563790813088417,0.9741575717926025,neutral,-0.005433341488242149
